The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Nayak & PACs
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagdish Umakant Nayak, Promoter and Managing Director of Clinitech Laboratory Ltd, bought 9,600 equity shares in the open market on March 30, 2026, on the BSE. Along with his Persons Acting in Concert (PACs — family members including Jyoti, Ashutosh, Ananya, Anant, Siddhesh, and Eshwari Nayak), his combined holding has risen from 14,65,400 shares (64.20%) to 14,75,000 shares (64.62%) of the company's total equity share capital of 22,82,400 shares. The change represents a 0.42 percentage point increase in promoter group stake. The acquisition was made entirely through the open market route, and the disclosure is being filed under Regulation 29(2) of the SEBI Takeover Regulations, 2011.
The promoter group continues to hold a strong majority (64.62%) after this purchase. While the buy signals promoter confidence, the small 0.42% incremental size means it is unlikely to have a meaningful effect on the stock price or overall control dynamics.